European self-care industry association, AESGP, sees positives and negatives in the European Commission’s long-awaited proposals for revising the European Union’s legislative framework for pharmaceuticals.
AESGP has welcomed that there are no substantial changes to marketing authorization procedures, as well as proposed changes aiming to reduce regulatory burden, such as unlimited authorization periods and the removal of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?